Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with ...
New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
Zacks.com on MSN10d
AMGN Posts Upbeat Data on Uplizna From Myasthenia Gravis StudyNew late-stage study data shows that treatment with Amgen's Uplizna for a year improves disease symptoms in patients with ...
Zacks Investment Research on MSN9d
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of ...
US biotech major Amgen has announced new data from the Phase III MINT trial of Uplizna (inebilizumab-cdon) in adults living with generalized myasthenia gravis (gMG).
Oppenheimer reiterates a Perform rating on Cartesian Therapeutics (RNAC) without a price target following the company’s Q4 report. The ...
Amgen (NasdaqGS:AMGN) has recently garnered attention due to promising Phase 3 MINT trial results for UPLIZNA in treating ...
with a statistically significant change from baseline in MG-ADL score for UPLIZNA (-4.2) compared with placebo (-2.2) at Week 26 for the combined study population. Also Read: Amgen And Kyowa Kirin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback